James Wilson edits the Pharma and Biotech desk at Trend & Ticker. He covers drug developers, clinical trial results, regulatory decisions and the business of pharmaceutical and biotechnology companies. His reporting draws on company releases, trial registries, FDA notices and SEC filings, and he checks each claim and figure against the original document before publication.
Recent Updates
-
Ionis (IONS) partner Roche shows sefaxersen cut IgA nephropathy proteinuria 43.1% in Phase 3Roche gave the first effect size from its IMAgINATION kidney trial at ASN Kidney Week, a clearer read for Ionis Pharmaceuticals Inc. (IONS) on a partnered drug that carries milestones and royalties. Sefaxersen cut proteinuria by 43.1% against placebo at 37 weeks in a Phase 3 trial in IgA nephropathy, according to data Ionis Pharmaceuticals Inc. (IONS) released on October 23. Roche Holding AG,...0 Comments 0 Shares 6 Views 0 ReviewsPlease log in to like, share and comment!
-
0 Comments 0 Shares 3 Views 0 Reviews
More Stories